March 10, 2022
NEJM publication of Novartis Kisqali Data Shows Longest Median Overall Survival Ever Reported in HR+/HER2- Advanced Breast Cancer
The New England Journal of Medicine (NEJM) published data showing the Phase III MONALEESA-2 trial for NovartIs’s Kisqali (ribociclib) plus letrozole demonstrated a statistically significant improvement in overall survival.
